Colorectal Cancer Screening and Diagnostic Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2030, Segmented By Screening Method (Fecal Occult Blood Tests (FOBT), Colonoscopy, Sigmoidoscopy, CT Colonography (Virtual Colono

Global Colorectal Cancer Screening and Diagnostic Market Size Expands at CAGR of 8.95% to Reach USD 26.71 Billion by 2030

Global Colorectal Cancer Screening and Diagnostic Market is flourishing because of the rising incidence of colorectal cancer and a growing focus on the treatment of the disease and the management of increasing healthcare expenditure.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Global Colorectal Cancer Screening and Diagnostic Market size at USD 15.97 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects the Global Colorectal Cancer Screening and Diagnostic Market size to expand at a CAGR of 8.95% reaching a value of USD 26.71 billion by 2030. The growing incidence of colorectal cancer and the expansion of government initiatives to support early detection and screening for cancer are two of the key growth drivers for the Global Colorectal Cancer Screening and Diagnostic Market. Moreover, increased private investments in the launch of innovative and advanced technologies in cancer screening and diagnostics are predicted to proliferate in the Global Colorectal Cancer Screening and Diagnostic Market over the forecast period.

Opportunity: Rising incidences of colorectal cancer

The primary driver of growth for the Global Colorectal Cancer Screening and Diagnostic Market is the disease's increasing prevalence. About 10% of cancer cases are colorectal cancer, which ranks as the third most frequent kind of cancer, according to the World Health Organization. Colorectal cancer is linked to bad lifestyle choices made by individuals, such as consuming large amounts of processed meat and limited vegetables and fruits, obesity, smoking, and drinking alcohol. Consequently, healthcare providers advise anyone aged over 50 years or those with a family history of colorectal cancer to undergo routine tests.

Impact of Escalating Geopolitical Tensions on Global Colorectal Cancer Screening and Diagnostic Market

The escalating geopolitical tensions are disrupting the growth of the Global Colorectal Cancer Screening and Diagnostic Market. For instance, Ukraine is a leading medical tourism destination for the diagnosis and treatment of cancer. However, Russia's invasion of Ukraine and the outbreak of war between the two countries led to the inaccessibility of healthcare services. According to a paper published in the National Center for Biotechnology Information, the conflict led to the displacement of patients to safer regions, particularly Europe, which overburdened the healthcare sector in these countries due to the large number of refugees. As a result, the inaccessibility of cancer screening and diagnosis hindered overall global market growth.

Global Colorectal Cancer Screening and Diagnostic Market

Segmental Coverage

Global Colorectal Cancer Screening and Diagnostic Market – By End User

Based on end user, the Global Colorectal Cancer Screening and Diagnostic Market is segmented into hospitals & clinics, diagnostic centers, and research institutes. The hospitals & clinics segment accounts for the highest market share owing to the high number of hospitals and the increasing number of awareness campaigns. Additionally, favorable reimbursement policies and insurance coverage also favor the growth of the hospital segment in the market. The diagnostic centers are predicted to register a substantial growth rate during the forecast period. The growth of diagnostics segment is attributed to the rising number of colonoscopies for colorectal cancer screening.

Global Colorectal Cancer Screening and Diagnostic Market - By Region

The in-depth research report on the Global Colorectal Cancer Screening and Diagnostic Market the market in a number of major countries across five major regions: North America, Europe, Asia Pacific (APAC), Latin America, and Middle East and Africa. North America dominates the Global Colorectal Cancer Screening and Diagnostic Market owing to the rising incidences of the disease. According to estimates by the American Society of Clinical Oncology, colorectal cancer is the fourth most diagnosed cancer in the United States, with an estimated 52,550 deaths in 2023. Colorectal cancer screenings are generally recommended for people over the age of 50. However, the Washington Post reports that colorectal cancer is increasingly gaining prevalence among American youth, which is anticipated to drive the demand for colorectal cancer screening and diagnosis in North America during the forecast period.

Competitive Landscape

Major players operating in the Global Colorectal Cancer Screening and Diagnostic Market include Epigenomics Inc., Exact Sciences Corporation, Eiken Chemical Co. Ltd, Polymedco Inc., F. Hoffmann-La Roche AG, Siemens Healthineers AG, Sysmex Corporation, Olympus Corporation, Biocept Inc., and Pathway Genomics Corporation.

To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and the Global Colorectal Cancer Screening and Diagnostic Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Colorectal Cancer Screening and Diagnostic Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.


1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. Global Colorectal Cancer Screening and Diagnostic Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Increasing Incidence of Colorectal Cancer
3.2.1.2. Growing Healthcare Expenditure
3.2.2. Restraints
3.2.2.1. High Costs Associated with Colorectal Cancer Screening and Diagnostic Procedures
3.2.2.2. Lack of Awareness about Colorectal Cancer
3.2.3. Opportunities
3.2.3.1. Government Initiatives and Awareness Campaigns
3.2.3.2. Integration of Telemedicine and Digital Health Solutions
3.2.4. Challenges
3.2.4.1. Data Security and Privacy Concerns
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter’s Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. Global Colorectal Cancer Screening and Diagnostic Market Overview
4.1. Market Size & Forecast, 2019–2030
4.1.1. By Value (USD Billion)
4.2. Market Share and Forecast
4.2.1. By Screening Method
4.2.1.1. Fecal Occult Blood Tests (FOBT)
4.2.1.2. Colonoscopy
4.2.1.3. Sigmoidoscopy
4.2.1.4. CT Colonography (Virtual Colonoscopy)
4.2.1.5. Stool DNA Testing
4.2.2. By Diagnostic Tool
4.2.2.1. Biopsy
4.2.2.2. Blood Tests
4.2.2.3. Imaging Techniques
4.2.3. By End User
4.2.3.1. Hospitals and Clinics
4.2.3.2. Diagnostic Centers
4.2.3.3. Research Institutes
4.2.4. By Region
4.2.4.1. North America
4.2.4.2. Europe
4.2.4.3. Asia Pacific (APAC)
4.2.4.4. Latin America (LATAM)
4.2.4.5. Middle East and Africa (MEA)
5. North America Colorectal Cancer Screening and Diagnostic Market
5.1. Market Size & Forecast, 2019–2030
5.1.1. By Value (USD Billion)
5.2. Market Share & Forecast
5.2.1. By Screening Method
5.2.2. By Diagnostic Tool
5.2.3. By End User
5.2.4. By Country
5.2.4.1. United States
5.2.4.1.1. By Screening Method
5.2.4.1.2. By Diagnostic Tool
5.2.4.1.3. By End User
5.2.4.2. Canada
5.2.4.2.1. By Screening Method
5.2.4.2.2. By Diagnostic Tool
5.2.4.2.3. By End User
6. Europe Colorectal Cancer Screening and Diagnostic Market
6.1. Market Size & Forecast, 2019–2030
6.1.1. By Value (USD Billion)
6.2. Market Share & Forecast
6.2.1. By Screening Method
6.2.2. By Diagnostic Tool
6.2.3. By End User
6.2.4. By Country
6.2.4.1. Germany
6.2.4.1.1. By Screening Method
6.2.4.1.2. By Diagnostic Tool
6.2.4.1.3. By End User
6.2.4.2. United Kingdom
6.2.4.2.1. By Screening Method
6.2.4.2.2. By Diagnostic Tool
6.2.4.2.3. By End User
6.2.4.3. Italy
6.2.4.3.1. By Screening Method
6.2.4.3.2. By Diagnostic Tool
6.2.4.3.3. By End User
6.2.4.4. France
6.2.4.4.1. By Screening Method
6.2.4.4.2. By Diagnostic Tool
6.2.4.4.3. By End User
6.2.4.5. Spain
6.2.4.5.1. By Screening Method
6.2.4.5.2. By Diagnostic Tool
6.2.4.5.3. By End User
6.2.4.6. Belgium
6.2.4.6.1. By Screening Method
6.2.4.6.2. By Diagnostic Tool
6.2.4.6.3. By End User
6.2.4.7. Russia
6.2.4.7.1. By Screening Method
6.2.4.7.2. By Diagnostic Tool
6.2.4.7.3. By End User
6.2.4.8. The Netherlands
6.2.4.8.1. By Screening Method
6.2.4.8.2. By Diagnostic Tool
6.2.4.8.3. By End User
6.2.4.9. Rest of Europe
6.2.4.9.1. By Screening Method
6.2.4.9.2. By Diagnostic Tool
6.2.4.9.3. By End User
7. Asia Pacific Colorectal Cancer Screening and Diagnostic Market
7.1. Market Size & Forecast, 2019–2030
7.1.1. By Value (USD Billion)
7.2. Market Share & Forecast
7.2.1. By Screening Method
7.2.2. By Diagnostic Tool
7.2.3. By End User
7.2.4. By Country
7.2.4.1. China
7.2.4.1.1. By Screening Method
7.2.4.1.2. By Diagnostic Tool
7.2.4.1.3. By End User
7.2.4.2. India
7.2.4.2.1. By Screening Method
7.2.4.2.2. By Diagnostic Tool
7.2.4.2.3. By End User
7.2.4.3. Japan
7.2.4.3.1. By Screening Method
7.2.4.3.2. By Diagnostic Tool
7.2.4.3.3. By End User
7.2.4.4. South Korea
7.2.4.4.1. By Screening Method
7.2.4.4.2. By Diagnostic Tool
7.2.4.4.3. By End User
7.2.4.5. Australia & New Zealand
7.2.4.5.1. By Screening Method
7.2.4.5.2. By Diagnostic Tool
7.2.4.5.3. By End User
7.2.4.6. Indonesia
7.2.4.6.1. By Screening Method
7.2.4.6.2. By Diagnostic Tool
7.2.4.6.3. By End User
7.2.4.7. Malaysia
7.2.4.7.1. By Screening Method
7.2.4.7.2. By Diagnostic Tool
7.2.4.7.3. By End User
7.2.4.8. Singapore
7.2.4.8.1. By Screening Method
7.2.4.8.2. By Diagnostic Tool
7.2.4.8.3. By End User
7.2.4.9. Vietnam
7.2.4.9.1. By Screening Method
7.2.4.9.2. By Diagnostic Tool
7.2.4.9.3. By End User
7.2.4.10. Rest of APAC
7.2.4.10.1. By Screening Method
7.2.4.10.2. By Diagnostic Tool
7.2.4.10.3. By End User
8. Latin America Colorectal Cancer Screening and Diagnostic Market
8.1. Market Size & Forecast, 2019–2030
8.1.1. By Value (USD Billion)
8.2. Market Share & Forecast
8.2.1. By Screening Method
8.2.2. By Diagnostic Tool
8.2.3. By End User
8.2.4. By Country
8.2.4.1. Brazil
8.2.4.1.1. By Screening Method
8.2.4.1.2. By Diagnostic Tool
8.2.4.1.3. By End User
8.2.4.2. Mexico
8.2.4.2.1. By Screening Method
8.2.4.2.2. By Diagnostic Tool
8.2.4.2.3. By End User
8.2.4.3. Argentina
8.2.4.3.1. By Screening Method
8.2.4.3.2. By Diagnostic Tool
8.2.4.3.3. By End User
8.2.4.4. Peru
8.2.4.4.1. By Screening Method
8.2.4.4.2. By Diagnostic Tool
8.2.4.4.3. By End User
8.2.4.5. Rest of LATAM
8.2.4.5.1. By Screening Method
8.2.4.5.2. By Diagnostic Tool
8.2.4.5.3. By End User
9. Middle East & Africa Colorectal Cancer Screening and Diagnostic Market
9.1. Market Size & Forecast, 2019–2030
9.1.1. By Value (USD Billion)
9.2. Market Share & Forecast
9.2.1. By Screening Method
9.2.2. By Diagnostic Tool
9.2.3. By End User
9.2.4. By Country
9.2.4.1. Saudi Arabia
9.2.4.1.1. By Screening Method
9.2.4.1.2. By Diagnostic Tool
9.2.4.1.3. By End User
9.2.4.2. UAE
9.2.4.2.1. By Screening Method
9.2.4.2.2. By Diagnostic Tool
9.2.4.2.3. By End User
9.2.4.3. Qatar
9.2.4.3.1. By Screening Method
9.2.4.3.2. By Diagnostic Tool
9.2.4.3.3. By End User
9.2.4.4. Kuwait
9.2.4.4.1. By Screening Method
9.2.4.4.2. By Diagnostic Tool
9.2.4.4.3. By End User
9.2.4.5. South Africa
9.2.4.5.1. By Screening Method
9.2.4.5.2. By Diagnostic Tool
9.2.4.5.3. By End User
9.2.4.6. Nigeria
9.2.4.6.1. By Screening Method
9.2.4.6.2. By Diagnostic Tool
9.2.4.6.3. By End User
9.2.4.7. Algeria
9.2.4.7.1. By Screening Method
9.2.4.7.2. By Diagnostic Tool
9.2.4.7.3. By End User
9.2.4.8. Rest of MEA
9.2.4.8.1. By Screening Method
9.2.4.8.2. By Diagnostic Tool
9.2.4.8.3. By End User
10. Competitive Landscape
10.1. List of Key Players and Their Offerings
10.2. Global Colorectal Cancer Screening and Diagnostic Market Share Analysis, 2023
10.3. Competitive Benchmarking, By Operating Parameters
10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
11. Impact of Escalating Geopolitical Tensions on Global Colorectal Cancer Screening and Diagnostic Market
12. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
12.1. Epigenomics Inc.
12.2. Exact Sciences Corporation
12.3. Eiken Chemical Co. Ltd
12.4. Polymedco Inc
12.5. F. Hoffmann-La Roche AG
12.6. Siemens Healthineers AG
12.7. Sysmex Corporation
12.8. Olympus Corporation
12.9. Biocept Inc.
12.10. Pathway Genomics Corporation
12.11. Other Prominent Players
13. Key Strategic Recommendations
14. Research Methodology
14.1. Qualitative Research
14.1.1. Primary & Secondary Research
14.2. Quantitative Research
14.3. Market Breakdown & Data Triangulation
14.3.1. Secondary Research
14.3.2. Primary Research
14.4. Breakdown of Primary Research Respondents, By Region
14.5. Assumptions & Limitations

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings